Profound Medical Prices $20M Public Offering of 2.67M Shares

TL;DR

**Profound Medical is selling 2.67 million new shares at $7.50 each, raising $20 million, which means dilution for current shareholders but fresh cash for the company.**

AI Summary

Profound Medical Corp. announced on December 27, 2023, the pricing of an underwritten public offering of 2,666,667 common shares at a price of $7.50 per share. This offering aims to raise approximately $20 million in gross proceeds for the company. For investors, this means a potential dilution of existing shares, but also an injection of capital that could fund future growth and operations.

Why It Matters

This public offering will dilute existing shareholders' ownership but provides Profound Medical with a significant cash infusion to fund its operations and growth initiatives.

Risk Assessment

Risk Level: medium — The offering introduces share dilution, which can negatively impact the value of existing shares, but the capital raised could also reduce financial risk.

Analyst Insight

An investor should evaluate the company's use of the $20 million raised. While dilution is a short-term negative, if the capital is deployed effectively for growth or to strengthen the balance sheet, it could be a long-term positive. Monitor future announcements on capital allocation.

Key Numbers

• 2,666,667 — Common Shares Offered (The total number of new shares being sold in the public offering.)
• $7.50 — Price Per Share (The price at which each common share is being sold in the offering.)
• $20,000,002.50 — Gross Proceeds (The approximate total amount of money Profound Medical expects to raise before expenses from this offering.)
• December 27, 2023 — Date of Material Change (The date Profound Medical announced the pricing of its public offering.)

Key Players & Entities

• Profound Medical Corp. (company) — the company conducting the public offering
• Rashed Dewan (person) — Chief Financial Officer who signed the 6-K filing
• $7.50 (dollar_amount) — price per common share in the public offering
• 2,666,667 (dollar_amount) — number of common shares offered
• December 27, 2023 (date) — date of the material change announcement

Forward-Looking Statements

• The capital raised from this offering will be used to fund Profound Medical's ongoing operations and potentially accelerate product development or market expansion. (Profound Medical Corp.) — medium confidence, target: Q1 2025
• The stock price of Profound Medical Corp. may experience short-term downward pressure due to the dilution from the new share offering. (Profound Medical Corp.) — high confidence, target: Q1 2024

FAQ

Filing Documents

• tm241343d2_6k.htm (6-K) — 9KB
• tm241343d2_ex99-1.htm (EX-99.1) — 19KB
• 0001104659-24-000413.txt ( ) — 29KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PROFOUND MEDICAL CORP. (Registrant) Date: January 2, 2024 /s/ Rashed Dewan Rashed Dewan Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR